An 8-week, multicenter study to evaluate the efficacy and safety of the combination of valsartan/HCTZ [hydrochlorothiazide]/amlodipine compared to valsartan/HCTZ, valsartan/amlodipine, and HCTZ/amlodipine in patients with moderate to severe hypertension.

Trial Profile

An 8-week, multicenter study to evaluate the efficacy and safety of the combination of valsartan/HCTZ [hydrochlorothiazide]/amlodipine compared to valsartan/HCTZ, valsartan/amlodipine, and HCTZ/amlodipine in patients with moderate to severe hypertension.

Completed
Phase of Trial: Phase III

Latest Information Update: 03 Aug 2017

At a glance

  • Drugs Amlodipine/valsartan/hydrochlorothiazide (Primary) ; Amlodipine; Hydrochlorothiazide; Valsartan
  • Indications Hypertension
  • Focus Registrational; Therapeutic Use
  • Sponsors Novartis
  • Most Recent Events

    • 07 Nov 2011 Actual end date (Aug 2007) added as reported by ClinicalTrials.gov.
    • 18 Dec 2009 Secondary efficacy and tolerability analysis published in Advances in Therapy.
    • 09 May 2009 Results presented at the 24th Annual Scientific Meeting of the American Society of Hypertension
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top